Thromb Haemost 2001; 86(05): 1170-1175
DOI: 10.1055/s-0037-1616046
Review Article
Schattauer GmbH

Prospective Randomised Open-label Comparison of Danaparoid with Dextran 70 in the Treatment of Heparin-induced Thrombocytopaenia with Thrombosis

A Clinical Outcome Study
B. H. Chong
1   Prince of Wales, Sydney
A. S. Gallus
2   Flinders Medical Centre, Adelaide, Australia
J. F. Cade
3   Royal Melbourne, Melbourne
H. Magnani
4   Organon, Oss, The Netherlands
A. Manoharan
5   St. George, Sydney
M. Oldmeadow
6   Alfred Hospitals, Melbourne
C. Arthur
7   Royal North Shore Hospitals, Sydney
K. Rickard
8   Royal Prince Alfred, Sydney
J. Gallo
9   Lidcombe, Sydney
J. Lloyd
10   Royal Adelaide Hospital, Adelaide, Australia
P. Seshadri
11   Repatriation General Hospital, Adelaide, Australia
C. N. Chesterman
1   Prince of Wales, Sydney
The Australian HIT Study Group › Author Affiliations
This work was supported, in part, by an unrestricted grant from Organon, Oss, The Netherlands. The authors wish to thank Dr. Val Gebski and Ms. Jackie Fabri of the National Health & Medical Research Council Clinical Trials Centre, Camperdown, NSW, Australia, for the statistical analyses. We are also indebted to the physicians who allowed their patients to participate in the study and to the other doctors/health care staff who assisted in various ways.
Further Information

Publication History

Received 13 March 2001

Accepted after revision 04 July 2001

Publication Date:
13 December 2017 (online)


Aim: To compare clinical outcomes in a randomised comparison of treatment with danaparoid sodium (a heparinoid), or dextran 70, for heparin-induced thrombocytopaenia (HIT) plus thrombosis. Methods: Forty-two patients with recent thrombosis and a clinical diagnosis of probable HIT who presented at ten Australian hospitals during a study period of six and one half years were randomly assigned to open-label treatment with intravenous danaparoid or dextran 70, each combined with oral warfarin. Thirty-four patients (83%) had a positive platelet aggregation or 14C-serotonin release test for HIT antibody. Twenty-five received danaparoid as a bolus injection of 2400 anti-Xa units followed by 400 units per hour for 2 h, 300 units per hour for 2 h, and then 200 units per hour for five days. Seventeen received 1000 mL dextran 70 on day one and then 500 mL on days 2-5. Patients were reviewed daily for clinical evidence of thrombus progression or resolution, fresh thrombosis or embolism, bleeding or other complications. The primary trial endpoint was the proportion of thromboembolic events with complete clinical resolution by the time of discharge from hospital. Results: With danaparoid, there was complete clinical recovery from 56% of thromboembolic events compared to 14% after dextran 70 (Odds Ratio 10.53, 95% Confidence Interval 1.6–71.4; p = 0.02). Clinical recovery with danaparoid was complete or partial in 86% of thromboembolic events compared with 53% after dextran 70 (Odds Ratio 4.55, 95% Confidence Interval 1.2–16.7; p = 0.03). Overall clinical effectiveness of danaparoid was rated as high or moderate in 88% of patients compared with 47% for dextran 70 (p = 0.01). One patient given danaparoid died of thrombosis compared with three patients given dextran 70. The platelet count returned to normal after a mean of 6.7 days with danaparoid and 7.3 days with dextran 70. There was no major bleeding with either treatment. Conclusion: danaparoid plus warfarin treatment for HIT with thrombosis is effective, safe, and superior to dextran 70 plus warfarin.

  • References

  • 1 Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Sem Hematol 1998; 35 (Suppl. 04) 9-16.
  • 2 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. The N Engl J Med 2001; 344: 1286-92.
  • 3 Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
  • 4 Chong BH. Heparin-induced thrombocytopaenia. ANZ J Med 1992; 22: 145-52.
  • 5 Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopaenia – Association of thrombotic complications with a heparin-dependent IgG antibody which induces platelet aggregation, release, and thromboxane synthesis. Lancet 1982; ii: 1246-8.
  • 6 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 536-40.
  • 7 Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost 1998; 79: 1-7.
  • 8 Danhof M, de Boer A, Magnani H, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992; 22: 73-84.
  • 9 Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65.
  • 10 Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54: 903-24.
  • 11 Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592-6.
  • 12 Ortel TH, Gockerman JP, Califf RM, McCann RL, O’Connor CM, Metzler DM. et al. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost 1992; 67: 292-6.
  • 13 Burkhard-Meier U, Sohngen D, Schultheiss H-P, Greinacher A, Schwartz-kopff B, Vogt M. et al. Heparin-induced thrombocytopenia Type II: successful use of Orgaran (ORG 10172) in intensive care patients. Intensive Care Med 1995; 21: 542-4.
  • 14 Chong BH, Magnani H. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992; 22: 85-91.
  • 15 Magnani H. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997; 8: 74-81.
  • 16 Ortel TH, Chong BH. New treatment options for heparin-induced thrombocytopenia. Sem Hematol 1998; 35 (Suppl. 04) 74-81.
  • 17 Magnani H. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61.
  • 18 Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler B. et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999; 99: 73-80.
  • 19 Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B. et al. Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients with Heparin-Induced Thrombocytopenia. Circulation 1999; 100: 587-93.
  • 20 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepidurin and its therapeutic APTT range. Blood 2000; 96: 846-51.
  • 21 Lewis BE, Wallis DE, Matthai W. Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: A prospective, historical controlled study. J Am Coll Cardiol 2000; 35 suppl A 266A (Abstract).
  • 22 Clagett GP, Anderson FA, Geerts W, Heit JA, Knudson M, Lieberman JR. et al. Prevention of venous thromboembolism. Chest 1998; 114 suppl 531S-60S.
  • 23 Chong BH. Annotation: Heparin-induced thrombocytopaenia. Brit J Haematol 1995; 89: 431-9.
  • 24 Zeger S, Liang K. Longitudinal Data Analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30.